Literature DB >> 8484627

Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial.

M H Sanders1, N B Kern, J P Costantino, R A Stiller, K Studnicki, J Coates, S Orris, S Schimerman.   

Abstract

We tested the hypothesis that a prescription for positive-pressure therapy (including pressure level, patient-device interface, and positive-pressure modality, e.g., CPAP or BiPAP) for obstructive sleep apnea (OSA) can be developed on the same night as the polysomnographic (PSG) diagnosis is made. Fifty consecutive patients with OSA in whom a partial-night PSG diagnosis was made (PSGD) underwent a therapeutic trial of positive-pressure therapy during the remainder of the night (PSG-PPP). The average apnea index during PSGD was 54.96 +/- 36.3 (mean +/- SD). On a subsequent full-night PSG (PSG-PPF), the prescription was tested. Thirty-one of the 50 patients were satisfactorily treated with CPAP, without variation of the interface during both PSG-PPP and PSG-PPF. In these patients the average pressure prescription while receiving PSG-PPF was statistically higher than during PSG-PPP (11.77 +/- 3.6 versus 10.56 +/- 3.6 cm H2O, respectively, p = 0.002). In 14 of these 31 patients (45%) some alteration in pressure requirement was necessary during PSG-PPF. Eleven patients required 2.5 cm H2O higher pressure and three patients required 5 cm H2O higher pressure during PSG-PPF than during PSG-PPP. There was a change of interface across the two therapeutic trials in 15 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8484627     DOI: 10.1164/ajrccm/147.5.1169

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Timing, number and complexities of sleep studies.

Authors:  K P Strohl
Journal:  Sleep Breath       Date:  1997-06       Impact factor: 2.816

2.  Effect of uvulopalatopharyngoplasty on CPAP compliance.

Authors:  Sang Duk Hong; Hyo Yeol Kim; Hyun-Jin Cho; Min-Seok Jang; Hun-Jong Dhong; Seung-Kyu Chung
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-10       Impact factor: 2.503

Review 3.  Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea.

Authors:  R R Grunstein
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

4.  Comparison of two in-laboratory titration methods to determine effective pressure levels in patients with obstructive sleep apnoea.

Authors:  M P Bureau; F Sériès
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

5.  The use of a predicted CPAP equation improves CPAP titration success.

Authors:  James A Rowley; Abdul G S Tarbichi; M Safwan Badr
Journal:  Sleep Breath       Date:  2005-03       Impact factor: 2.816

6.  Upper airway surgery: the effect on nasal continuous positive airway pressure titration on obstructive sleep apnea patients.

Authors:  Adriane Iurck Zonato; Lia Rita A Bittencourt; Fernanda Louise Martinho; Luiz Carlos Gregório; Sergio Tufik
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05       Impact factor: 2.503

7.  The impact of split-night versus traditional sleep studies on CPAP compliance.

Authors:  Jacob Collen; Aaron Holley; Christopher Lettieri; Anita Shah; Stuart Roop
Journal:  Sleep Breath       Date:  2009-08-28       Impact factor: 2.816

8.  Adequacy of prescribing nasal continuous positive airway pressure therapy for the sleep apnoea/hypopnoea syndrome on the basis of night time respiratory recording variables.

Authors:  J M Montserrat; A Alarcón; P Lloberes; E Ballester; C Fornas; R Rodriguez-Roisin
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

9.  Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea.

Authors:  Clete A Kushida; Alejandro Chediak; Richard B Berry; Lee K Brown; David Gozal; Conrad Iber; Sairam Parthasarathy; Stuart F Quan; James A Rowley
Journal:  J Clin Sleep Med       Date:  2008-04-15       Impact factor: 4.062

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.